期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

新型脂糖肽类抗生素:特拉万星 被引量：5

Telavancin:a novel lipoglycopeptide antibiotic
下载PDF
导出
摘要 特拉万星（telavancin）属脂糖肽类，是万古霉素的半合成衍生物，为快速杀菌的注射用抗生素，用于治疗耐药革兰阳性菌特别是甲氧西林耐药金葡菌（MRsA）感染。该药最初由Theravance公司研发，
作者 陈春辉 李光辉
机构地区 复旦大学附属华山医院抗生素研究所
出处 《中国感染与化疗杂志》 CAS 北大核心 2012年第2期153-157,共5页 Chinese Journal of Infection and Chemotherapy
关键词 特拉万星 脂糖肽类 革兰阳性菌
分类号 R978.16 [医药卫生—药品]
  • 相关文献

参考文献27

  • 1Vibativ[package insert]. South San Francisco, Calif: Thera- varmelne; 2009[EB/OL]. http://www, astellas, us/docs/ us/VIBATIV_PI Final. pdf. Accessed April 28, 2010.
  • 2Higgins DL, Chang R, Debabov DV, et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall syn- thesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus [J]. Antimicrob Agents Chemother, 2005,49(3) : 1127-1134.
  • 3Pace JL, Judice JK. Telavancin (Theravance)[J]. Curr Opin Investig Drugs, 2005, 6(2) :216-225.
  • 4Pankuch GA, Appelbaum PC. Postantibiotic effects of tela- vancin against 16 Gram-positive organisms[J]. Antimicrob Agents Chemother, 2009, 53(10) : 1275-1277.
  • 5Shaw JP, Seroogy J, Kaniga K, et al. Pharmaeokinetics, ser- um inhibitory and bactericidal activity, and safety of telavan- ein in healthy subjects[J]. Antimicrob Agents Chemother. 2005,49( 1 ) : 195-201.
  • 6Vibativ (telavancin) Package insert. Deerfield, IL: Astellas Pharma, Inc. : 2009. Duchin K, Shaw J, Seroogy J, et al. Effect of hemodialysis on single dose pharmacokinetics of telavancin [abstract P8973 [C]. Program and abstracts of the 15th European Con- gress of Clinical Microbiology and Infectious Disease (Copen- hagen, Denmark). 2005.
  • 7Wong SL, Shaw JPI Barriere SL, et al. Pharmacokinetics of intravenous telavancin in subjects with hepatic impairment fabstract A-19513 [C]. In program and abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemo- therapy (San Francisco, CA). 2006.
  • 8Wong SL, Barriere SL, Kitt MM, et al. Multiple-dose phar- macokinetics of intravenous telavancin in healthy male and fe- male subjects[J]. J Antimicrob Chemother, 2008, 62 (4) : 780-783.
  • 9Wong SL, Barriere SL, Kitt MM, et al. Multiple-dose phar- macokinetics of intravenous telavancin in healthy male and fe- male subjects[J]. J Antimicrob Chemother, 2008, 62(4): 780-783.
  • 10Sun HK, Duchin K, Nightingale CH, et al. Tissue penetra- tion of telavancin after intravenous administration in healthy subjects[J]. Antimicrob Agents Chemother, 2006, 50 (2) : 788-790.

同被引文献38

  • 1董玲.氨甲基膦酸的合成[J].南通大学学报（自然科学版）,2005,4(2):17-20. 被引量：2
  • 2Goldstein E J C, Citron D M, Merriam C V, et al. In vitro activities of the new semisynthetic glycopeptides telavancin (TD-6424), vancomycin, daptomycin, linezolid and four comparator agents against anaerobic gram-positive species and Corynebacterium spp[J]. Antimicrob Agents Chemother, 2004, 48(6): 2149-2152.
  • 3Smith K, Gemmell C G, Lang S. Telavancin shows superior activity to vancomycin with multidrug-resistant Staphylococcus aureus in a range of in vitro biofilm models [J]. Eur J Clin MicrobiolInfectDis, 2013, 32 (10): 1327-1332.
  • 4Guskey M T, Tsuji B T. A Comparative Review of the Lipoglycopeptides: Oritavancin, Dalbavancin, and Telavanein[J]. Pharmacotherapy, 2010, 30: 80-94.
  • 5Krause K M, Renelli M, Difumorum S, et al. In vitro activity of telavancin against resistant gram-positive bacteria[J]. Antimicrob Agents Chemother, 2008, 52(7):2647-2652.
  • 6Hegde S S, Reyes N, Wiens T, et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram- positive bacteria[J]. Antimicrob Agents Chemother, 2004, 48(8): 3043-3050.
  • 7Yin Y L, Calhoun J H, Theodore S, et al. Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: Studies with a rabbit model [J]. 3 Antimicrob Chemother, 2009, 63(2): 357-360.
  • 8Amanatullah D F, Lopez M J, Gosselin R C, et al. Case report: artificial elevation of prothrombin time by telavancin [J]. Clin Orthop Relat Res, 2013, 471 : 332-335.
  • 9Hebeisen P, Krauss I K, Angehrn P, et al. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci [J]. Antimicrob Agents Chemother, 2001, 45(3): 825-836.
  • 10Jones M E. In-vitro profile of a new β-1actam, ceftobiprole, with activity against methiciUin-resistant Staphylococcus aureus [J]. Clin Microbiol Infect, 2007, 13(2): 17-24.

引证文献5

二级引证文献14

中国感染与化疗杂志
2012年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部